Baseline, study end AMSS values and ∆AMSS broken down into the somatic, psychological, and sexual subscales
| AMSS startified by subscales (somatic, psychological and sexual) | P | TU |
|---|---|---|
| Somatic subscale (Q1–5, Q9, and Q10) (7–35) | ||
| Median (IQR) baseline AMSS, n | 17 (13, 21), n = 44 | 19 (15, 24), n = 38 |
| Median (IQR) AMSS 30-week | 15 (11, 20) | 16.5 (14, 22) |
| Median (IQR) ∆AMSS | –1 (–3, 1) | –2 (–4, 1) |
| p (sign-rank) | 0.0048 | 0.017 |
| Psychological subscale (Q6–8, Q11, and Q13) (5–25) | ||
| Median (IQR) baseline AMSS, n | 9 (6, 11), n = 45 | 10 (8, 14), n = 35 |
| Median (IQR) AMSS 30-week | 8 (6, 11) | 9 (7, 12) |
| Median (IQR) ∆AMSS | –1 (–2, 1) | –1 (–3, 0) |
| p (sign-rank) | 0.23 | 0.0039 |
| Sexual subscale (Q12, Q14–17) (5–25) | ||
| Median (IQR) baseline AMSS, n | 12 (10, 17), n = 45 | 15 (11, 18.5), n = 36 |
| Median (IQR) AMSS 30-week | 13 (9, 16) | 13 (9, 16) |
| Median (IQR) ∆AMSS | 0 (–2, 1) | –2 (–4.5, –0.5) |
| p (sign-rank) | 0.66 | 0.0011 |
p < 0.05 is considered significant. ∆AMSS: changes in ageing male symptom scale; IQR: interquartile range; P: placebo; Q: questionnaire; TU: testosterone undecanoate